Advertisement

Results of a Nonrandomized Trial in Malignant Melanoma Patients (Clark’s Stages III–V) Treated by Post-Surgical Chemoimmunotherapy

  • B. Serrou
  • H. Pujol
  • J. Domas
  • L. Gauci
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 68)

Abstract

Malignant melanoma is a poor prognosis disease when centered in the trunk region and whenever node infiltration has occurred [7, 14]. For this reason, we initiated in 1972 a nonrandomized study of complementary chemoimmunotherapy treatment following radical surgery. Chemoimmunotherapy was modulated according to postchemotherapeutic observations concerning immunologic restoration and overshoot phenomena [8, 12]. This therapeutic practice has subsequently been confirmed experimentally.

Keywords

Nonrandomized Trial Historical Control Group Historical Group Trunk Region Primary Cutaneous Melanoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Beretta, G.: Controlled study for prolonged chemotherapy, immunotherapy and chemotherapy plus immunotherapy as an adjuvant to surgery in stage I–II malignant melanoma: preliminary report. In: Immunotherapy of cancer: present status of trials in man. Terry, W. D., Windhorst, D. (eds.), p. 19. New York: Raven Press 1978.Google Scholar
  2. 2.
    Caraux, J., Serrou, B.: The binding of autologous erythrocytes by human lymphocytes. Biomedicine (in press) (1978).Google Scholar
  3. 3.
    Caraux, J., Thierry, C., Serrou, B.: Human autologous rosettes. II. Prognostic significance of variations in autologous rosette forming cells in the peripheral blood of cancer patients. J.N.C.I. (in press) (1978).Google Scholar
  4. 4.
    Cunningham, T. J., Schoenfeld, D., Nathanson, L., Wolter, J., Patterson, W. B., Cohen, M. H.: A controlled study of adjuvant therapy in patients with stage I and II malignant melanoma. In: Immunotherapy of cancer: present status of trials in man. Terry, W. D., Windhorst, D. (eds.), p. 19. New York: Raven Press 1978.Google Scholar
  5. 5.
    Eilber, F. R., Morton, D. L., Holmes, E. C., Sparks, F. C., Ramming, K. P.: Adjuvant immunotherapy with B.C.G. in treatment of regional lymph-node metastases from malignant melanoma. N. Engl. J. Med. 294, 237–240 (1976).PubMedCrossRefGoogle Scholar
  6. 6.
    Gauci, L., Caraux, J., Thierry, C., Pujol, H., Serrou, B.: Modifications of the immune status induced in malignant melanoma patients by chemo-immunotherapy and immunotherapy. In: Human lymphocyte differentiation. Its application to cancer. Serrou, B., Rosenfeld, C. (eds.). New York: North-Holland 1978 (in press).Google Scholar
  7. 7.
    Gupta, T. K. D.: Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study. Ann. Surg. 186, 201–209 (1977).PubMedCrossRefGoogle Scholar
  8. 8.
    Hersh, E. M., Whitecar, J. P., McCredie, K. B., Bodey, G. P., Freireich, E. J.: Immunocompetence, immunosuppression and prognosis in acute leukemia. N. Engl. J. Med. 1211, 285–291 (1971).Google Scholar
  9. 9.
    Jewell, W. R., Thomas, J. H., Sterchi, J. M., Morse, P. A., Humphrey, L. J.: Critical analysis of treatment of stage II and stage III melanoma patients with immunotherapy. Ann. Surg. 183, 543–548 (1976).PubMedCrossRefGoogle Scholar
  10. 10.
    Morton, D. L., Holmes, E. C., Eilber, F. R., Sparks, F., Ramming, K. P.: Adjuvant immunotherapy of malignant melanoma: preliminary results of a randomized trial in patients with lymph node metastases. In: Immunotherapy of cancer: present status of trials in man. Terry, W. D., Windhorst, D. (eds.), p. 57. New York: Raven Press 1978.Google Scholar
  11. 11.
    Pinsky, C. M., Hirshaut, Y., Wanebo, H. J., Hilal, E. Y., Fortner, J. G., Mike, V., Schottenfeld, D., Oettgen, H. F.: Surgical adjuvant immunotherapy with B.C.G. in patients with malignant melanoma: results of a prospective randomized trial. In: Immunotherapy of cancer: present status of trials in man. Terry, W. D., Windhorst, D. (eds.), p. 27. New York: Raven Press 1978.Google Scholar
  12. 12.
    Serrou, B., Dubois, J. B.: Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors. Biomedicine 23, 41–45 (1975).PubMedGoogle Scholar
  13. 13.
    Serrou, B., Caraux, J., Domas, J., Grenier, J., Thierry, C., Pujol, H.: Value of some immunological parameters to evaluate the prognosis of melanoma patients treated by chemo-immunotherapy Proc. ASCO 19, 349 (Abs. C-170) (1978).Google Scholar
  14. 14.
    Veronesi, U., Cascinelli, N., Preda, F.: Prognosis of malignant melanoma according to regional metastases. Am. J. Roentgenol. 111, 301–309 (1971).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • B. Serrou
  • H. Pujol
  • J. Domas
  • L. Gauci

There are no affiliations available

Personalised recommendations